Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review

References

• TaylorDPatonCKapurSPrescribing Guidelines in Psychiatry12th edWest Sussex, UKJohn Wiley & Sons2015
   Google Scholar
• AzermaiMDealing with behavioral and psychological symptoms of dementia: a general overviewPsychol Res Behav Manag2015818118526170729
   PubMed Web of Science ®Google Scholar
• NagataTShinagawaSNakajimaSClassification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer’s disease: analysis of the CATIE-AD StudyJ Alzheimers Dis20165083984526836181
   PubMed Web of Science ®Google Scholar
• TibleOPRieseFSavaskanEvon GuntenABest practice in the management of behavioural and psychological symptoms of dementiaTher Adv Neurol Disord20171029730928781611
   PubMed Web of Science ®Google Scholar
• PreussUWWongJWMKollerGTreatment of behavioral and psychological symptoms of dementia: a systematic reviewPsychiatr Pol201650679715 Polish27847922
   PubMed Web of Science ®Google Scholar
• AzermaiMPetrovicMElseviersMMSystematic appraisal of dementia guidelines for the management of behavioural and psychological symptomsAgeing Res Rev201211788621856452
   PubMed Web of Science ®Google Scholar
• SelbaekGKirkevoldØEngedalKThe course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes – a 12-month follow-up studyAm J Geriatr Psychiatry20081652853618591573
   PubMed Web of Science ®Google Scholar
• BallardCCorbettAManagement of neuropsychiatric symptoms in people with dementiaCNS Drugs201024972973920806986
   PubMed Web of Science ®Google Scholar
• TrifiróGSultanaJSpinaEAre the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studiesDrug Saf20143750152024859163
   PubMed Web of Science ®Google Scholar
• ProtopopováDMasopustJVališMPoužití antipsychotik u nemocných s demencíCesk Slov Neurol201578111158162
   Google Scholar
• ReusVIFochtmannLJEylerAEThe American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementiaAm J Psychiatry201617354354627133416
   PubMed Web of Science ®Google Scholar
• van der SpekKGerritsenDLSmalbruggeMOnly 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-studyInt Psychogeriatr2016281589159527587349
   PubMed Web of Science ®Google Scholar
• CasanovaMFStarksteinSEJellingerKAClinicopathological correlates of behavioral and psychological symptoms of dementiaActa Neuropathol2011122211713521455688
   PubMed Web of Science ®Google Scholar
• AbrahaIRimlandJMTrottaFMSystematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop seriesBMJ Open201773e012759
   PubMed Web of Science ®Google Scholar
• KuronenMKautiainenHKarppiPHartikainenSKoponenHAntipsychotic drug use and associations with neuropsychiatric symptoms in persons with impaired cognition: a cross-sectional studyNord J Psychiatry20167062162527300080
   PubMed Web of Science ®Google Scholar
• RozziniLChiloviBVContiMEfficacy of SSRIs on cognition of Alzheimer’s disease patients treated with cholinesterase inhibitorsInt Psychogeriatr20102211411919552831
   PubMed Web of Science ®Google Scholar
• NowrangiMALyketsosCGRosembergPBPrinciples and management of neuropsychiatric symptoms in Alzheimer’s dementiaAlzheimers Res Ther2015711227391771
   PubMed Web of Science ®Google Scholar
• SeitzDPAndunuriNGillSSGruneirAHerrmannNRochonPAntidepressants for agitation and psychosis in dementiaCochrane Database Syst Rev2011162CD008191
   Google Scholar
• SeitzDPGillSSHerrmannNPharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic reviewInt Psychogeriatr20132518520323083438
   PubMed Web of Science ®Google Scholar
• SchneiderLSFrangakisCDryeLTCitAD Research GroupHeterogeneity of treatment response to citalopram for patients with Alzheimer’s disease with aggression or agitation: the CitAD randomized clinical trialAm J Psychiatry201617346547226771737
   PubMed Web of Science ®Google Scholar
• LeonpacherAKPetersMEDryeLTCitAD Research GroupEffects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD studyAm J Psychiatry201617347348027032628
   PubMed Web of Science ®Google Scholar
• ViscogliosiGChiriacIMEttorreEEfficacy and safety of citalopram compared to atypical antipsychotics on agitation in nursing home residents with Alzheimer dementiaJ Am Med Dir Assoc20171879980228739492
   PubMed Web of Science ®Google Scholar
• LebertFStekkeWHasenbroekxCPasquierFFrontotemporal dementia: a randomised, controlled trial with trazodoneDement Geriatr Cogn Disord20041735535915178953
   PubMed Web of Science ®Google Scholar
• CakirSKulaksizogluIBThe efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot studyNeuropsychiatr Dis Treat2008496396619183787
   PubMedGoogle Scholar
• YehYCOuyangWCMood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update reviewKaohsiung J Med Sci20122818519322453066
   PubMed Web of Science ®Google Scholar
• SivalRCHaffmansPMJansenPADuursmaSAEikelenboomPSodium valproate in the treatment of aggressive behavior in patients with dementia – a randomized placebo controlled clinical trialInt J Geriatr Psychiatry20021757958512112183
   PubMed Web of Science ®Google Scholar
• KonovalovSMuraleeSTampiRRAnticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature reviewInt Psychogeriatr20082029330818047764
   PubMed Web of Science ®Google Scholar
• CampbellNAyubABoustaniMAImpact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: a meta-analysisClin Interv Aging2008371972819281064
   PubMed Web of Science ®Google Scholar
• KishiTMatsunagaSIwataNThe effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysisNeuropsychiatr Dis Treat2017131909192828790827
   PubMed Web of Science ®Google Scholar
• TanCCYuJTWangHFEfficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysisJ Alzheimers Dis201441261563124662102
   PubMed Web of Science ®Google Scholar
• WangJYuJTMengXFPharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysisJ Neurol Neurosurg Psychiatry201586110110924876182
   PubMed Web of Science ®Google Scholar
• ChenRChanPTChuHTreatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysisPLoS One2017128e018358628827830
   PubMed Web of Science ®Google Scholar
• SavaskanEMuellerHHoerrRTreatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trialsInt Psychogeriatr20172119
   Google Scholar
• SaarelainenLTaipaleHKoponenMvon GuntenAGauthierSThe incidence of benzodiazepine and related drug use in persons with and without Alzheimer’s diseaseJ Alzheimers Dis20164980981826484930
   PubMed Web of Science ®Google Scholar
• TampiRRTampiDJEfficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trialsAm J Alzheimers Dis Other Demen20142956557425551131
   PubMed Web of Science ®Google Scholar
• GentileSSecond-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomized controlled trialsPsychopharmacology201021211912920661553
   PubMed Web of Science ®Google Scholar
• US FDAPublic Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances2005 Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinfor-mationforpatientsandproviders/drugsafetyinformationforheathcare-professionals/publichealthadvisories/ucm053171.htmAccessed January 20, 2018
   Google Scholar
• KalesHCKimHMZivinKRisk of mortality among individual antipsychotics in patients with dementiaAm J Psychiatry2012169717922193526
   PubMed Web of Science ®Google Scholar
• SuhGHGreenspanAJChoiSKComparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementiaInt J Geriatr Psychiatry20062165466016821257
   PubMed Web of Science ®Google Scholar
• MaherARTheodoreGSummary of the comparative effectiveness review on off-label use of atypical antipsychoticsJ Manag Care Pharm2012185 suppl BS1S20
   PubMedGoogle Scholar
• SchneiderLSTariotPNDagermanKSCATIE-AD Study GroupEffectiveness of atypical antipsychotic drugs in patients with Alzheimer’s diseaseN Engl J Med20063551525153817035647
   PubMed Web of Science ®Google Scholar
• TanLWangHFWangJEfficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysisAlzheimers Res Ther2015712025897331
   PubMed Web of Science ®Google Scholar
• BarnesTRBanerjeeSCollinsNTreloarAMcIntyreSMPatonCAntipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health servicesBr J Psychiatry201220122122622790679
   PubMed Web of Science ®Google Scholar
• YoshidaKRobertsRSuzukiTLack of early improvement with antipsychotics is a marker for subsequent nonresponse in behavioral and psychological symptoms of dementia: analysis of CATIE-AD dataAm J Geriatr Psychiatry20172570871628215900
   PubMed Web of Science ®Google Scholar
• ReevesSBertrandJMcLachlanEA population approach to guide amisulpride dose adjustments in older patients with Alzheimer’s diseaseJ Clin Psychiatry201778e844e85128858444
   PubMed Web of Science ®Google Scholar
• SteinbergMLysketosCGAtypical antipsychotic use in patients with dementia: managing safety concernsAm J Psychiatry201216990090622952071
   PubMed Web of Science ®Google Scholar
• StahlSMThe Prescriber’s Guide4th edCambridgeCambridge Universtiy Press2013
   Google Scholar
• BallardCLanaMMTheodoulouMOn behalf of the investigators DART ADA randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART AD trial)PLoS Medicine200854587599
   Web of Science ®Google Scholar
• BallardCHowardRNeuroleptic drugs in dementia: benefits and harmNat Rev Neurosci20067649250016715057
   PubMed Web of Science ®Google Scholar
• WolfALeuchtSPajonkFGDo antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trialsEur Arch Psychiatry Clin Neurosci201726718719827530185
   PubMed Web of Science ®Google Scholar
• WangPSSchneeweissSAvornJRisk of death in elderly users of conventional vs. atypical antipsychotic medicationsN Engl J Med2005353222335234116319382
   PubMed Web of Science ®Google Scholar
• SchneeweissSSetoguchiSBrookhartADormuthCWangPSRisk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patientsCMAJ200717662763217325327
   PubMed Web of Science ®Google Scholar
• KalesHCValensteinMKimHMMortality risk in patients with dementia treated with antipsychotics versus other psychiatric medicationsAm J Psychiatry20071641568157617898349
   PubMed Web of Science ®Google Scholar
• US FDAInformation on conventional antipsychotics2008 Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrug-safetyinformationforpatientsandproviders/ucm107211.htmAccessed January 20, 2018
   Google Scholar
• HuybrechtsKFGerhardTCrystalSDifferential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort studyBMJ2012344e97722362541
   PubMed Web of Science ®Google Scholar
• BallardCHanneyMLTheodoulouMThe dementia antipsychotic withdrawal trial (D A R T - A D); long-term follow-up of a randomised placebo-controlled trialLancet Neurol2009815115719138567
   PubMed Web of Science ®Google Scholar
• SacchettiETurrinaCValsecchiPCerebrovascular accidents in elderly people treated with antipsychotic drugsDrug Saf20103327328820297860
   PubMed Web of Science ®Google Scholar
• HsuWTEsmaily-FardALaiCCAntipsychotics and the risk of cerebrovascular accident: a systematic review and meta-analysis of observational studiesJ Am Med Dir Assoc20171869269928431909
   PubMed Web of Science ®Google Scholar
• TrifiróGAntipsychotic drug use and community-acquired pneumoniaCurr Infect Dis Rep20111326226821394430
   PubMedGoogle Scholar
• NielsenJGraffCKantersJKToftETaylorDMeyerJMAssessing QT interval prolongation and its associated risks with antipsychoticsCNS Drugs20112547349021649448
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc20126061663122376048
   PubMed Web of Science ®Google Scholar
• MasopustJMalýRVališMRisk of venous thromboembolism during treatment with antipsychotic agentsPsychiatry Clin Neurosci20126654155223252920
   PubMed Web of Science ®Google Scholar
• SchmedtNGarbeEAntipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementiaJ Clin Psychopharmacol20133375377824052055
   PubMed Web of Science ®Google Scholar
• ZhengLMackWJDagermanKSMetabolic changes associated with second generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD studyAm J Psychiatry200916658359019369318
   PubMed Web of Science ®Google Scholar
• RondanelliMSarraSAntonielloNNo effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer’s diseaseMinerva Med20069714715116760853
   PubMedGoogle Scholar
• DeclercqTPetrovicMAzermaiMWithdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaCochrane Database Syst Rev20133CD007726
   PubMed Web of Science ®Google Scholar
• PatelANLeeSAndrewsHFPrediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinationsAm J Psychiatry201717436236927855483
   PubMed Web of Science ®Google Scholar
• PasqualettiGTogniniSCalsolaroVPoliniAMonzaniFPotential drug-drug interactions in Alzheimer patients with behavioral symptomsClin Interv Aging2015101457146626392756
   PubMed Web of Science ®Google Scholar
• CarnahanRMLundBCPerryPJChrischillesEAThe concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?J Am Geriatr Soc2004522082208715571547
   PubMed Web of Science ®Google Scholar